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Abstract
Background
Recent studies demonstrate that rabies post-exposure prophylaxis (RPEP) in international
travelers is suboptimal, with only 5–20% of travelers receiving rabies immune globulin
(RIG) in the country of exposure when indicated. We hypothesized that travelers may not be
receiving RIG appropriately, and practices may vary between countries. We aim to describe
the characteristics of travelers who received RIG and/or RPEP during travel.
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Methodology/Principal findings
We conducted a multi-center review of international travelers exposed to potentially rabid
animals, collecting information on RPEP administration. Travelers who started RPEP before
(Group A) and at (Group B) presentation to a GeoSentinel clinic during September 2014–
July 2017 were included. We included 920 travelers who started RPEP. About two-thirds of
Group A travelers with an indication for rabies immunoglobulin (RIG) did not receive it. Trav-
elers exposed in Indonesia were less likely to receive RIG in the country of exposure (rela-
tive risk: 0.30; 95% confidence interval: 0.12–0.73; P = 0.01). Travelers exposed in Thailand
[Relative risk (RR) 1.38, 95% Confidence Interval (95% CI): 1.0–1.8; P = 0.02], Sri Lanka
(RR 3.99, 95% CI: 3.99–11.9; P = 0.013), and the Philippines (RR 19.95, 95% CI: 2.5–
157.2; P = 0.01), were more likely to receive RIG in the country of exposure.
Conclusions/Significance
This analysis highlights gaps in early delivery of RIG to travelers and identifies specific coun-
tries where travelers may be more or less likely to receive RIG. More detailed country-level
information helps inform risk education of international travelers regarding appropriate
rabies prevention.
Author summary
International travelers may be exposed to rabid animals while traveling abroad. Current
guidelines recommended that any traveler who was not been vaccinated against rabies
before travel and sustained an animal exposure putting him at risk for rabies required
rabies post-exposure prophylaxis including rabies immunoglobulin administration in
addition to rabies vaccine as soon as possible. Available data indicate that only a small pro-
portion of travelers received rabies immunoglobulin in the country of exposure when
indicated. In this multi-center survey, we collected information on rabies post-exposure
prophylaxis administration in international travelers exposed to potentially rabid animals.
We observed that about two-thirds of travelers with an indication for rabies immunoglob-
ulin who started their post-exposure prophylaxis during travel did not receive it. This
analysis identified specific countries where travelers may be more or less likely to receive
rabies immunoglobulin and helps inform risk education of international travelers regard-
ing appropriate rabies prevention. In our analysis, Bali, Indonesia, was the most common
location to have an exposure to a potentially rabid animal, but very few travelers received
rabies immunoglobulin in Indonesia when indicated. By contrast, travelers exposed in
Thailand, Sri Lanka and the Philippines were more likely to receive rabies immunoglobu-
lin in the country of exposure.
Introduction
International travelers may be exposed to rabid animals while traveling abroad. The estimated
incidence of potential rabies exposures requiring post-exposure prophylaxis (RPEP) among
international travelers is 0.4 per 1,000 per month of stay [1]. The proportion of international
travelers requiring RPEP at GeoSentinel clinics among other patients increased from <0.5% of
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visits in 2003 to>2% in 2012. The increase may be due to greater diversity of travel destina-
tions and number of international travelers [2].
Limited data are available on the proportion of international travelers that receive pre-travel
rabies vaccination, but vaccine provision is usually guided by individual risk assessment and
cost [1]. At the time of writing, World Health Organization (WHO) guidelines recommended
that any traveler who had not received a three-dose pre-exposure prophylaxis (PrEP) and sus-
tained a category III exposure—transdermal bite(s) or scratch(es), licks to broken skin, mucus
membrane contamination, or contact with a bat—required rabies immunoglobulin (RIG)
administration in addition to rabies vaccine [3]. Pre-exposure immunization obviates the need
for RIG after exposure [3]. Recent studies demonstrate that only 5–20% of travelers received
RIG in the country of exposure when indicated [4–12] (Table 1).
The objective of this analysis was to conduct a multi-center review of international travelers
exposed to potentially rabid animals. We describe the characteristics of travelers who received
RIG and/or RPEP during travel in the region of exposure, to determine whether receipt of RIG
varied by country or region.
Methods
Data source
GeoSentinel is a global clinician-based sentinel surveillance system that monitors travel-related
illness and other conditions among international travelers. It was established in 1995 as a col-
laboration between the Centers for Disease Control and Prevention (CDC) and the Interna-
tional Society of Travel Medicine. GeoSentinel currently consists of 70 specialized travel and
tropical medicine clinical sites in 31 countries [13]. GeoSentinel’s data collection protocol has
been reviewed by the CDC’s National Center for Emerging and Zoonotic Infectious Diseases
Table 1. Summary of studies showing proportion of patients with indication for rabies immunoglobulin who received rabies immunoglobulin in the country of
exposure.
Year Number of
patients
Study design Proportion of patients with indication for RIG who received RIG in the
country of exposure2
Reference
1997–
2005
261 Multicenter (France, Australia, New Zealand) 11.2% [4]
2000–
2009
139 Unicenter (United Kingdom) 3.8% [5]
1998–
2012
363 Unicenter (New Zealand) 20.3% [6]
2000–
2012
1,126 Unicenter (Denmark) 10.3% [7]
2008–
2010
45 Multicenter (France, Australia, New Zealand,
Singapore) 1
5.3% [8]
2006–
2012
106 Unicenter (Republic of Korea) 9.4% [9]
2007–
2011
780 Unicenter (Australia) 9.0% [10]
2008–
2012
136 Unicenter (Australia) 4.0% [11]
2009–
2010
65 Unicenter (Australia) 7.8% [12]
1Patients exposed in Bali, only
2According to the WHO criteria (category III exposure in patients who received no, one, or two doses of rabies vaccine, before travel) [3]
WHO = World Health Organization, RIG = rabies immunoglobulin
https://doi.org/10.1371/journal.pntd.0006951.t001
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and is classified as public health surveillance and not human subjects research. Additional eth-
ics clearance was obtained by participating sites, as required by their respective institutions.
Survey of GeoSentinel travelers with a potential rabies exposure
We analyzed records submitted to GeoSentinel of international travelers with exposure to a
potentially rabid animal. Demographics and travel history, place of exposure, and animal
involved in the exposure were recorded. Travelers who started RPEP before (Group A) and
at (Group B) presentation to a GeoSentinel clinic during September 2014–July 2017 were
included. Among travelers in the former group, data were collected and assessed for type of
exposure [3], rabies PrEP, occurrences where RPEP with or without RIG should have been
administered, and differences between international travelers who received RIG in the country
of exposure and those who did not (relative risk). We excluded records if they were not travel-
related or the exposure country was unascertainable.
Statistical analysis
Data were managed using Microsoft Access (Redmond, Washington, USA). Demographic
analyses were descriptive; for the binary outcome variable of receiving RIG in the country of
exposure, relative risks (RR) and 95% confidence intervals (95% CI) were determined. Statisti-
cal significance was defined as P<0.05. All analyses were performed using SAS version 9.4
(Cary, NC, USA).
Results
We examined 958 records; 38 were excluded (Fig 1). The analysis included 920 international
travelers; 517 (56.2%) started RPEP before presenting to a GeoSentinel clinic (Group A), and
403 (43.8%) started RPEP at a GeoSentinel clinic (Group B). Travelers were assessed at 33 Geo-
Sentinel clinics in 21 countries. Median age was 30 years (range 0–87), 52.3% were female, and
39.8% did not seek pre-travel advice (Table 2). The most frequent purpose of travel was tour-
ism (731 travelers; 79.5%), followed by travelers visiting friends and relatives (103 travelers;
11.2%). Over 98% of travelers were seen as outpatients. Most travelers were exposed in Asia
(697 travelers; 75.9%); 550 travelers (59.8%) were exposed in Southeast Asia; 115 travelers
(12.5%) were exposed in South Central Asia; and 32 (3.5%) were exposed in North East Asia.
Thailand, Indonesia, and Nepal accounted for over 50% of all exposures; the most frequent
location of exposure was Bali, Indonesia [64 of 325 (19.7%) travelers with information avail-
able]. A greater proportion of travelers from Group A (versus Group B), were visiting friends
and relatives (VFRs) (16.1% versus 6.0%) or were exposed in Southeast Asia (68.5% versus
48.6%). Detailed data will be made available on request.
Nine (3%) travelers in Group A had received a complete 3-dose PrEP regimen; five received
two-dose and five single-dose PrEP regimens. Most sought health care on the day of animal
exposure (median 0 days; range 0–366 days; interquartile range: 0–1 days). Travelers were
exposed most frequently to dogs (260; 50.3%), non-human primates (NHPs) (182; 35.2%), cats
(59; 11.4%), or bats (4; 2.1%). Travelers to Thailand, Indonesia, and Cambodia were exposed
more frequently to NHPs than to other animals, and tourists were exposed more frequently to
NHPs than were VFRs (42.6% and 3.6%, respectively). Among Group A exposures, 362
(70.0%) were classified as WHO category III, 112 (21.7%) were category II, and 17 (3.3%) were
category I [3]. Only 133 (25.7%) exposures occurred in rural areas, while 210 (40.6%) were in
cities [the remaining 174 (33.7%) were unknown]. A total of 125 (24.2%) travelers reported
being exposed through an unprovoked bite, and 112 (21.7%) reported visiting an animal
reserve.
Rabies post-exposure prophylaxis in travelers
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In Group A, 353 (68.3%) had an indication for RIG according to WHO criteria (Fig 1). Of
these, 126 (35.7%) received RIG; 87 (24.7%) travelers received RIG in the country of exposure.
The remaining 227 travelers (64.3%) did not receive RIG (Fig 1). Among the 227 travelers who
did not receive RIG although indicated, 144 (63.4%) presented to a GeoSentinel clinic when
RIG administration was no longer indicated (>7 days after the first dose of vaccine) [3]. Trav-
elers exposed in Indonesia were less likely to receive RIG in the country of exposure (RR: 0.30;
95% CI: 0.12–0.73; P = 0.01) (Table 3).
Travelers exposed in Thailand (RR 1.38, 95% CI: 1.0–1.8; P = 0.02], Sri Lanka (RR 3.99,
95% CI: 3.99–11.9; P = 0.013), and the Philippines (RR 19.95, 95% CI: 2.5–157.2; P = 0.01),
were more likely to receive RIG in the country of exposure. There were no significant
Fig 1. Number of international travelers receiving RPEP reported to GeoSentinel, September 2014–July 2017 (RIG: Rabies
immunoglobulin; RPEP: Rabies post-exposure prophylaxis).
https://doi.org/10.1371/journal.pntd.0006951.g001
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differences in demographic, travel, or exposure characteristics between those who received
RIG and those who did not. None of the travelers included in this analysis were known to have
developed rabies.
Discussion
This analysis supports the findings of previous studies that reported rabies exposures among
international travelers occur most frequently in Asia and that tourists sustain more rabies
exposures than other types of travelers [2]. Of major concern is the finding that almost 65% of
travelers in Group A with an indication for RIG did not receive it. This finding is likely multi-
factorial and may be due to limited availability of RIG at both the national and primary care
levels of the health system, which may be due to procurement difficulties, the need to store
RIG at 2–8˚C [14], and its high cost. In addition, there may be insufficient awareness of indica-
tions for the use of RIG. Information about RIG availability at travel destinations can be diffi-
cult to find, and supply may be inconsistent. One survey, although biased toward international
travel medicine organizations, demonstrated that less than half of clinics surveyed in Asia
had access to RIG [15]. Similarly, a survey of US Embassy medical staff who provided health
advice, conducted by the same group of investigators, found that possible rabies exposures
accounted for about 2% of health inquiries. About two-thirds of the respondents in the latter
survey reported that RIG was available for travelers in the country where they were based.
Notably in Southeast and East Asia, human RIG was often not available [16]. In our analysis,
Table 2. Demographics, travel characteristics, and clinical presentation of travelers reported to GeoSentinel who received rabies post-exposure prophylaxis, Sep-
tember 2014–July 2017 (N = 920).
Travelers receiving an RPEP
diagnosis
(N = 920)
Travelers who started RPEP before presenting to
a GeoSentinel clinic
(N = 517)
(Group A)
Travelers who did not start RPEP before presenting
to a GeoSentinel clinic
(N = 403)
(Group B)
Median age (range) in
years
30 (0–87)1 29 (1–87)2 31 (0–81)3
Female
n (%)
481 (52.3) 266 (51.5) 215 (53.5)
Top three reasons for
travel
n (%)
Tourism: 731 (79.5)
VFR: 103 (11.2)
Business/corporate/
conference: 44 (4.8)
Tourism: 401 (77.6)
VFR: 83 (16.1)
Business/corporate/conference: 20 (3.9)
Tourism: 330 (81.9)
Business/corporate/conference: 24 (6.0)
VFR: 20 (5.0)
Pre-travel encounter
n (%)
Yes: 158 (17.2)
No: 366 (39.8)
Don’t know: 396 (43.0)
Yes: 79 (15.3)
No: 189 (36.6)
Don’t know: 249 (48.1)
Yes: 79 (19.6)
No: 177 (43.9)
Don’t know: 147 (36.5)
Top five regions of
exposure
n (%)
Southeast Asia: 550 (59.8)
South Central Asia: 115 (12.5)
North Africa: 66 (7.2)
North East Asia: 32 (3.5)
Sub-Saharan Africa: 30 (3.2)
Southeast Asia: 354 (68.5)
South Central Asia: 44 (8.5)
North Africa: 43 (8.3)
North East Asia: 22 (4.3)
Middle East: 15 (3.0)
Southeast Asia: 196 (48.6)
South Central Asia: 71 (17.6)
North Africa: 23 (5.7)
Sub-Saharan Africa: 21 (5.2)
South America: 18 (4.5)
Top five countries of
exposure
n (%)
Thailand: 271 (29.5)
Indonesia: 142 (15.4)
Nepal: 48 (5.2)
Vietnam: 43 (4.7)
Cambodia: 35 (3.8)
Thailand: 196 (37.9)
Indonesia: 82 (16.1)
Algeria: 23 (4.5)
Cambodia: 23 (4.5)
Vietnam: 23 (4.5)
Thailand: 75 (18.6)
Indonesia: 60 (14.9)
Nepal: 47 (11.7)
Vietnam: 20 (5.0)
Cambodia: 12 (3.0)
India: 12 (3.0)
RPEP = rabies post-exposure prophylaxis, VFR = visiting friends and relatives
1Of 910 with information available
2Of 509 with information available
https://doi.org/10.1371/journal.pntd.0006951.t002
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Bali, Indonesia, was the most common location to have an exposure to a potentially rabid ani-
mal, but very few travelers received RIG in Indonesia when indicated. Since more than 90%
of travelers were not completely vaccinated before traveling, and over 70% of travelers sus-
tained a category III exposure, it is imperative to identify high-risk areas where RIG may not
Table 3. Relative risk of receiving rabies immunoglobulin in the country of exposure when indicated, by traveler and exposure characteristics, September 2014–July
2017 (N = 304).
Characteristic RIG given in country of
exposure (N = 87)
RIG not given in country of
exposure (N = 217)
Relative risk of receiving RIG in the
country of exposure (95% CI)
P
value
Median age (range) in
years
32 (1–87)1 30 (2–79)
Female
n (%)
45 (51.7) 101 (46.5) 1.11 (0.9–1.4) 0.40
Travel reason
n (%)
Tourism 66 (75.9) 169 (77.9) 0.97 (0.8–1.1) 0.71
VFR 17 (19.5) 35 (16.1) 1.21 (0.7–2.4) 0.47
Business 3 (3.5) 7 (3.2) 1.07 (0.3–4.0) 0.92
Missionary 0 (0) 2 (0.9) 0.50 (0.0–10.2) 0.65
Education 1 (1.2) 2 (0.9) 1.25 (0.1–13.6) 0.86
Migrant worker 0 (0) 1 (0.5) 0.83 (0.0–20.1) 0.91
Migration 0 (0) 1 (0.5) 0.83 (0.0–20.1) 0.91
Pre-travel rabies
immunization
n (%)
None 83 (95.4) 200 (92.2) 1.04 (1.0–1.1) 0.26
Unknown 2 (2.3) 9 (4.2) 0.55 (0.1–2.5) 0.44
One dose 1 (1.2) 4 (1.8) 0.62 (0.1–5.5) 0.67
Two doses 1 (1.2) 4 (1.8) 0.62 (0.1–5.5) 0.67
Countries of exposure
n (%)
Thailand 43 (49.4) 78 (39.5) 1.38 (1.0–1.8) 0.02
Indonesia 5 (5.8) 42 (19.4) 0.30 (0.1–0.7) 0.01
India 3 (3.4) 13 (6.0) 0.58 (0.2–2.0) 0.38
China 1 (1.2) 12 (5.5) 0.21 (0.0–1.6) 0.13
Algeria 6 (6.9) 7 (3.2) 2.14 (0.7–6.2) 0.16
Philippines 8 (9.2) 1 (0.5) 19.95 (2.5–157.2) 0.01
Sri Lanka 8 (9.2) 5 (2.3) 3.99 (1.3–11.9) 0.013
Exposure location
n (%)
City 35 (40.2) 90 (41.5) 0.97 (0.7–1.3) 0.84
Unknown 32 (36.8) 72 (33.2) 1.11 (0.8–1.5) 0.55
Rural 20 (23.0) 55 (25.4) 0.91 (0.6–1.4) 0.67
Exposure activity
n (%)
Unknown 33 (37.9) 68 (31.3) 1.21 (0.9–1.7) 0.26
Unprovoked bite 23 (26.4) 49 (22.6) 1.17 (0.8–1.8) 0.47
Visiting animal park
or reserve
11 (12.6) 46 (21.2) 0.60 (0.3–1.1) 0.10
Walking 13 (14.9) 39 (18.0) 0.83 (0.5–1.5) 0.53
Other 4 (4.6) 9 (4.2) 1.11 (0.4–3.5) 0.86
Working with animals 1 (1.2) 6 (2.8) 0.42 (0.1–3.4) 0.41
Biking 2 (2.3) 0 (0) 12.39 (0.6–255.4) 0.10
Animal exposure
n (%)
Dog 53 (60.9) 109 (50.2) 1.21 (1.0–1.5) 0.08
Non-human primate 22 (25.3) 75 (34.5) 0.73 (0.5–1.1) 0.13
Cat 9 (10.3) 26 (12.0) 0.86 (0.4–1.8) 0.69
Other 2 (2.3) 6 (2.8) 0.83 (0.2–4.0) 0.82
Bat 1 (1.2) 1 (0.5) 2.47 (0.2–39.0) 0.52
RIG = rabies immunoglobulin, CI = confidence interval, VFR = visiting friends and relatives
1Of 86 travelers for whom information was available
https://doi.org/10.1371/journal.pntd.0006951.t003
Rabies post-exposure prophylaxis in travelers
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0006951 November 13, 2018 7 / 10
be widely available, such as Bali, so clinicians can encourage PrEP for travelers to these destina-
tions and educate travelers about steps to take if they sustain animal bites.
Following the Strategic Advisory Group of Experts on immunization (SAGE) meeting in
October 2017, WHO updated its recommendation for PrEP to two doses (days 0 and 7)
instead of three for immunocompetent individuals [17]. The rationale for this decision is that
several studies have demonstrated similar immunogenicity after one week compared to the
classical 3–4-week regimens [17]. Reducing the time frame and number of doses required for
PrEP would make it simpler and more cost-effective to implement in travelers as the classic
3-dose PrEP may be difficult to complete with the short average interval to departure (<21
days) of many travelers [18,19]. High vaccine cost is another reason for very low PrEP coverage
in travelers [20]. The new WHO recommendations will hopefully allow increasing rabies pre-
travel vaccination coverage in travelers to destinations where RIG administration is unlikely to
be provided despite being indicated. Although a single dose of PrEP should confer some pro-
tection, in the event of a potential rabies exposure, WHO recommends full RPEP including
RIG if indicated [17].
Given the travel and tropical medicine specialization of GeoSentinel sites, these data may
not be representative of all international travelers who receive RPEP or of travelers to a partic-
ular country or region. GeoSentinel data are not generalizable, so risk estimates of a particular
illness cannot be calculated. Additional information (i.e., urban or rural exposure, activity dur-
ing exposure, type of animal exposure, and pre-travel rabies immunization receipt) was col-
lected only on those travelers in Group A; data on whether RIG was provided or offered at
GeoSentinel clinic visits were not collected. Information collected from travelers who started
RPEP outside a GeoSentinel clinic was based upon patient report and clinical description of
the WHO exposure category and is subject to observer and recall bias. We did not collect data
on reasons for delay in treatment. Despite these limitations, this analysis identifies specific
countries where travelers may be more or less likely to receive RIG and helps inform education
of international travelers regarding appropriate rabies prevention.
Travelers should seek pre-travel advice before traveling abroad to ensure they receive
proper education on avoiding contact with animals and what to do after an animal exposure,
notably regarding indications for RIG. Since rabies exposures are often unpredictable, travelers
must be reminded that exposures often come from animals they perceive as unthreatening
(e.g., NHPs at tourist locations). When performing a risk assessment at a pre-travel consulta-
tion, health-care practitioners must assess if travelers’ destinations are at high risk for rabies
(and/or with unavailable RIG) and the possibility for additional or repeated exposures when
considering offering PrEP [21].
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